PolyPid Ltd.

PYPD

IL0011326795

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 14/03/2026 am IST			5-day change	1st Jan Change
4.190 ^USD	+0.48%		0.00%	-3.46%

25/02	PolyPid Ltd. Auditor Raises 'Going Concern' Doubt	CI
11/02	PolyPid Ltd., Q4 2025 Earnings Call, Feb 11, 2026

BMO Capital Adjusts PolyPid's Price Target to $25 from $27, Keeps Outperform Rating

Published on 08/11/2022 at 09:14 pm IST - Modified on 08/11/2022 at 09:15 pm IST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about PolyPid Ltd.

25/02	PolyPid Ltd. Auditor Raises 'Going Concern' Doubt	CI
11/02	PolyPid Ltd., Q4 2025 Earnings Call, Feb 11, 2026
11/02	PolyPid Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025	CI
16/12	Polypid names medtech veteran Brooke Story as board chairman	RE
16/12	PolyPid Ltd. Appoints Brooke Story as Chairman of the Board of Directors, Effective December 11, 2025	CI
11/12	PolyPid Ltd. - Special Call
03/12	PolyPid Ltd. Announces Positive Fda Pre-Nda Meeting Minutes for D-Plex100 Supporting Nda Submission	CI
03/12	Polypid announces positive FDA Pre-NDA meeting minutes	RE
12/11	PolyPid Ltd., Q3 2025 Earnings Call, Nov 12, 2025
12/11	PolyPid Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
12/11	Biopharma firm PolyPid's Q3 net loss narrows to $7.5 mln	RE
01/25/01	Polypid Ltd. to Present Its Positive Phase 3 Shield II Topline Results At the 2025 American College of Surgeons Clinical Congress	CI
16/25/16	PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection	CI
16/25/16	Polypid clears Israeli health ministry GMP inspection, nears commercial manufacturing for D-PLEX	RE
14/25/14	PolyPid Ltd., Q2 2025 Earnings Call, Aug 13, 2025

Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.

Employees

Sector

Pharmaceuticals

More about the company